Sal Daher, CFA

The longtime director of NIAID stressed that he was hypothesizing, based on how the vaccines have held up against other SARS-CoV-2 variants.

The Cuthbert hospital in Georgia was one of 19 rural hospitals in the U.S. that closed in 2020. That’s the largest number of such facilities to shut down in a single year since 2005.

Cigna Ventures and Bright’s majority shareholder, New Enterprise Associates, are contributing to the financing. It comes as Bright faces higher-than-expected medical costs during the pandemic.

New follow-up data for Roche’s Tecentriq-tiragolumab combination therapy in certain lung cancer patients have analysts sighing in relief that the anti-TIGIT element appears to be pulling its weight.

Among individuals seeking asylum in the U.S., forensic medical evaluations were often essential for being granted “immigration relief.”

A new Congressional report lays out controversial tactics used by the pharmaceutical industry to bolster profits.

A new poll shows that many people trust science and scientists. The biopharma industry needs to help maintain that trend.

Omicron is picking up speed in Europe, which has often served as a preview of what is heading the U.S.’s way.

Many parents hesitate to vaccinate their children against Covid-19. Weighing scientific evidence is healthy; embracing cynicism is not.

A federal judge has temporarily blocked a controversial California law that bans pay-to-delay deals between pharmaceutical companies.